AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37775584 — intervention group
Group type: COMPARATOR
Intervention: No material placed in the donor area; only the clot kept in position by sutures
Number of subjects: 42
Study 37775612 — intervention group
Group type: EXPERIMENTAL
Intervention: Chylomicron TG and ApoB-48 levels in individuals with type 2 diabetes
Number of subjects: 11
Study 37775612 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoB-48 particles in VLDL in individuals with type 2 diabetes
Number of subjects: 11
Study 37775612 — intervention group
Group type: COMPARATOR
Intervention: Fasting lipid profile
Number of subjects: 11
Study 37775611 — intervention group
Group type: EXPERIMENTAL
Intervention: POWER2DM (e-health system)
Number of subjects: 226
Study 37775611 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 226
Study 37775742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 1303
Study 37775744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzuloparib 100 mg bid plus apatinib 500 mg qd
Number of subjects: 52
Study 37775744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzuloparib plus apatinib
Number of subjects: 52
Study 37776001 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAN-intervention
Number of subjects: 61
Study 37776001 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 61
Study 37776194 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized heparin-protamine titration (IHPT)
Number of subjects: 132
Study 37776194 — intervention group
Group type: COMPARATOR
Intervention: Conventional heparinization and reversal (cACT)
Number of subjects: 132
Study 37776210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention focusing on exercise, diet, cognitive/social stimulation, and cardiovascular health
Number of subjects: 2000
Study 37776210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention focusing on exercise, diet, cognitive/social stimulation, and cardiovascular health (different intensity and accountability)
Number of subjects: 2000
Study 37776214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative hsCRP level quartiles (1-4)
Number of subjects: 1281
Study 37776214 — intervention group
Group type: COMPARATOR
Intervention: Cumulative times of high hsCRP levels (0-3 times)
Number of subjects: 1281
Study 37776235 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (infliximab and adalimumab)
Number of subjects: 324
Study 37776326 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19/22 dual-targeted CAR-T cell combined with tislelizumab (anti-PD-1 antibody)
Number of subjects: 16
Study 37776354 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive protein hydrolysate formula (EHF)
Number of subjects: 141
Study 37776354 — intervention group
Group type: COMPARATOR
Intervention: Cow milk formula (CMF)
Number of subjects: 141
Study 37776354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EHF and CMF
Number of subjects: 141
Study 37776390 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans inoculum (3.10)
Number of subjects: 26
Study 37776390 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans virulence expression
Number of subjects: 26
Study 37776390 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid composition
Number of subjects: 26
Study 37776478 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting intramuscular cabotegravir plus rilpivirine combination treatment every 4 weeks
Number of subjects: 0
Study 37776478 — intervention group
Group type: EXPERIMENTAL
Intervention: PIN questionnaire
Number of subjects: 0
Study 37776502 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-3-
Number of subjects: 36
Study 37776502 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced MRI
Number of subjects: 36
Study 37776510 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation using virtual reality glasses for 10 sessions over 5 weeks
Number of subjects: 12
Study 37776695 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-NiTi archwires
Number of subjects: 31
Study 37776695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular coaxial-NiTi archwires
Number of subjects: 31
Study 37776754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based neuroplasticity-oriented sensorimotor training (EG)
Number of subjects: 48
Study 37776754 — intervention group
Group type: COMPARATOR
Intervention: Tablet-based relaxation training (CG)
Number of subjects: 48
Study 37776872 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy, administered as four 28-day cycles with daratumumab at 16 mg/kg intravenously on days 1, 8, 15, and 22, and carfilzomib at 56 mg/m2.
Number of subjects: 123
Study 37776872 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy.
Number of subjects: 123
Study 37776876 — intervention group
Group type: EXPERIMENTAL
Intervention: TV005 vaccine
Number of subjects: 192
Study 37776876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 37776879 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorfenapyr-PY LLINs
Number of subjects: 4587
Study 37776879 — intervention group
Group type: EXPERIMENTAL
Intervention: PBO-PY LLINs
Number of subjects: 4587
Study 37776879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen-PY LLINs
Number of subjects: 4587
Study 37776879 — intervention group
Group type: COMPARATOR
Intervention: Standard PY LLINs
Number of subjects: 4587
Study 37776953 — intervention group
Group type: EXPERIMENTAL
Intervention: YK-029A 200 mg/d (dose-expansion phase)
Number of subjects: 108
Study 37776953 — intervention group
Group type: EXPERIMENTAL
Intervention: YK-029A (all doses during dose-escalation)
Number of subjects: 108
Study 37777018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (200 mg loading dose/50 mg daily)
Number of subjects: 65
Study 37777018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (100 mg/50 mg daily)
Number of subjects: 65
Study 37777018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (50 mg daily)
Number of subjects: 65
Study 37777018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (30 mg daily)
Number of subjects: 65
Study 37777018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib (10 mg daily)
Number of subjects: 65
Study 37777018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 37777256 — intervention group
Group type: EXPERIMENTAL
Intervention: mTICI 3
Number of subjects: 226
Study 37777256 — intervention group
Group type: COMPARATOR
Intervention: mTICI 2b
Number of subjects: 226
Study 37777255 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm-guided remote ECG monitoring with Zenicor-ECG device
Number of subjects: 1955
Study 37777270 — intervention group
Group type: EXPERIMENTAL
Intervention: External oblique intercostal plane block (EOIPB)
Number of subjects: 80
Study 37777270 — intervention group
Group type: COMPARATOR
Intervention: Standard multimodal analgesia (Control)
Number of subjects: 80
Study 37777515 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine synthesis capacity measured by PET imaging
Number of subjects: 0
Study 37777515 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine receptor availability measured by PET imaging
Number of subjects: 0
Study 37777684 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 100
Study 37777738 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided SBRT in 5 fractions (37.5 Gy over 10-14 days)
Number of subjects: 136
Study 37777738 — intervention group
Group type: COMPARATOR
Intervention: MR-guided SBRT in 2 fractions (25 Gy over 7-10 days)
Number of subjects: 136
Study 37777743 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (early treatment < 24 hours after PCI)
Number of subjects: 231
Study 37777743 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (intermediate treatment 24 to < 48 hours after PCI)
Number of subjects: 231
Study 37777743 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (late treatment 48 to 72 hours after PCI)
Number of subjects: 231
Study 37777806 — intervention group
Group type: EXPERIMENTAL
Intervention: AD(LATE-NC+) cases with comorbid TDP-43 pathology
Number of subjects: 98
Study 37777806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau biosensor cell line treated with sarkosyl-insoluble, brain-derived homogenates from AD(LATE-NC+) cases
Number of subjects: 98
Study 37777806 — intervention group
Group type: EXPERIMENTAL
Intervention: TDP-43 pathology
Number of subjects: 98
Study 37777806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 37777832 — intervention group
Group type: EXPERIMENTAL
Intervention: Xevinapant 200 mg/day on days 1-14 of a 3-week cycle
Number of subjects: 62
Study 37777832 — intervention group
Group type: EXPERIMENTAL
Intervention: Xevinapant 200 mg/day
Number of subjects: 62
Study 37777827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab combined with anti-PD-L1 durvalumab and chemotherapy
Number of subjects: 1605
Study 37777947 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomographic Angiography (CTA)
Number of subjects: 50
Study 37777947 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomographic Angiography (CTA) with Fractional Flow Reserve (FFR)
Number of subjects: 50
Study 37778085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical temporal summation at the knee
Number of subjects: 90
Study 37778226 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated dual antiplatelet therapy (DAPT)
Number of subjects: 2009
Study 37778226 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 2009
Study 37778226 — intervention group
Group type: COMPARATOR
Intervention: Peripheral vascular disease
Number of subjects: 2009
Study 37778226 — intervention group
Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 2009
Study 37778226 — intervention group
Group type: COMPARATOR
Intervention: Congestive heart failure
Number of subjects: 2009
Study 37778226 — intervention group
Group type: COMPARATOR
Intervention: Renal insufficiency/failure
Number of subjects: 2009
Study 37778226 — intervention group
Group type: COMPARATOR
Intervention: Predicted bleeding risk <4%
Number of subjects: 2009
Study 37778226 — intervention group
Group type: COMPARATOR
Intervention: Predicted bleeding risk ≥4%
Number of subjects: 2009
Study 37778356 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual, flexible antipsychotic reduction
Number of subjects: 253
Study 37778356 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 253
Study 37778358 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod (10 mg/kg)
Number of subjects: 131
Study 37778358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 37778363 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 209
Study 37778363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted nirmatrelvir
Number of subjects: 209
Study 37778363 — intervention group
Group type: COMPARATOR
Intervention: No study drug
Number of subjects: 209
Study 37778526 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 829
Study 37778613 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofilament Light Chain (NfL) at 24 hours
Number of subjects: 82
Study 37778613 — intervention group
Group type: EXPERIMENTAL
Intervention: Glial Fibrillary Acidic Protein (GFAP) at 48 hours
Number of subjects: 82
Study 37778613 — intervention group
Group type: COMPARATOR
Intervention: NfL and GFAP compared to Neuron Specific Enolase (NSE) at 48 hours
Number of subjects: 82
Study 37778954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 144
Study 37778954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy
Number of subjects: 144
Study 37778954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy with systematic sampling (strategy 4)
Number of subjects: 144
Study 37778954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy alone
Number of subjects: 144
Study 37778954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and MRI-targeted biopsy
Number of subjects: 144
Study 37779885 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative pupillometry (qPLR <4% and NPi ≤2)
Number of subjects: 0
Study 37779885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined quantitative pupillometry with neuron-specific enolase (NSE >60 μg L)
Number of subjects: 0
Study 37779885 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated quantitative pupillometry
Number of subjects: 0
Study 37779919 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) plus radiation therapy
Number of subjects: 0
Study 37779919 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan (IRIN)
Number of subjects: 0
Study 37779919 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan silicasome nanoparticles
Number of subjects: 0
Study 37780046 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Intervention with a team consisting of a pediatrician, psychologist, and physiotherapist.
Number of subjects: 677
Study 37780052 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb therapy
Number of subjects: 17
Study 37780052 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical cohort)
Number of subjects: 17
Study 37780064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 207
Study 37780065 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal processing tele-intervention (TPT)
Number of subjects: 95
Study 37780065 — intervention group
Group type: COMPARATOR
Intervention: Conventional language remediation (CLR)
Number of subjects: 95
Study 37780074 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment (discontinued)
Number of subjects: 37
Study 37780074 — intervention group
Group type: COMPARATOR
Intervention: REGN1103 (dupilumab surrogate)
Number of subjects: 37
Study 37780126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral overground gait-slip perturbation training (blocks of eight non-paretic and paretic slips followed by mixed blocks)
Number of subjects: 65
Study 37780126 — intervention group
Group type: COMPARATOR
Intervention: Control group (single non-paretic and paretic slip in random order)
Number of subjects: 65
Study 37780234 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose pneumococcal conjugate vaccine schedules
Number of subjects: 0
Study 37780234 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37780560 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care consultation (PC), 32 patients received PC consultation (30 were virtual)
Number of subjects: 39
Study 37780560 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care consultation (PC)
Number of subjects: 39
Study 37780560 — intervention group
Group type: COMPARATOR
Intervention: No palliative care consultation (Control group)
Number of subjects: 39
Study 37780620 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DMH patients (T2DM patients with hypertension)
Number of subjects: 92
Study 37780620 — intervention group
Group type: COMPARATOR
Intervention: T2DM patients (without hypertension)
Number of subjects: 92
Study 37780620 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 92
Study 37780701 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 500
Study 37780701 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 500
Study 37780770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid transvaginal natural orifice transluminal endoscopic surgery (hvNOTES)
Number of subjects: 0
Study 37781111 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional diet (MFD)
Number of subjects: 0
Study 37781111 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 0
Study 37781132 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid dosage of 0.8 mg
Number of subjects: 1567
Study 37781132 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid dosages ranging from 0 mg to 2.4 mg
Number of subjects: 1567
Study 37781132 — intervention group
Group type: COMPARATOR
Intervention: Folic acid dosages of 0, 0.4, 0.6, 0.8, 1.2, 1.6, 2.0 mg to 2.4 mg
Number of subjects: 1567
Study 37781156 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction tool and communication skills training
Number of subjects: 31
Study 37781158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib and bortezomib combination therapy
Number of subjects: 58
Study 37781158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance after combination therapy
Number of subjects: 58
Study 37781159 — intervention group
Group type: EXPERIMENTAL
Intervention: MAMMS (two-way SMS platform with MUAC tapes and weekly reminders)
Number of subjects: 1200
Study 37781159 — intervention group
Group type: EXPERIMENTAL
Intervention: MAMMS (two-way SMS platform)
Number of subjects: 1200
Study 37781159 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard care with routine community health volunteer services)
Number of subjects: 1200
Study 37781159 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard care)
Number of subjects: 1200
Study 37781160 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandebereho programme (15-session intervention)
Number of subjects: 1199
Study 37781161 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3759 at 200 mg bid
Number of subjects: 30
Study 37781161 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3759 at 300 mg bid
Number of subjects: 30
Study 37781161 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3759 (both doses combined)
Number of subjects: 30
Study 37781161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with osimertinib in a later-line setting
Number of subjects: 30
Study 37781161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated without osimertinib in a later-line setting
Number of subjects: 30
Study 37781463 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-lowering agents (GLAs) with proven cardiovascular benefits
Number of subjects: 800
Study 37781463 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-lowering agents (GLAs)
Number of subjects: 800
Study 37781539 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-derived extracellular vesicles
Number of subjects: 0
Study 37781539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammalian-derived extracellular vesicles
Number of subjects: 0
Study 37781539 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37781916 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (14% sustained CR for 2 years)
Number of subjects: 0
Study 37781916 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible SPARC downregulation in adult mice
Number of subjects: 0
Study 37781916 — intervention group
Group type: EXPERIMENTAL
Intervention: Deletion of SPARC in adipocytes
Number of subjects: 0
Study 37781916 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARC activation of NLRP3 inflammasome
Number of subjects: 0
Study 37781916 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulation of SPARC
Number of subjects: 0
Study 37781954 — intervention group
Group type: COMPARATOR
Intervention: LZV (single dose subcutaneously)
Number of subjects: 90259
Study 37781954 — intervention group
Group type: COMPARATOR
Intervention: RZV (two doses intramuscularly, two months apart)
Number of subjects: 90259
Study 37781954 — intervention group
Group type: EXPERIMENTAL
Intervention: LZV (single dose) and RZV (two doses)
Number of subjects: 90259
Study 37782145 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed insulin pump therapy
Number of subjects: 0
Study 37782145 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 0
Study 37782150 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 50% Maximal Inspiratory Pressure (MIP), 12 weeks, 3 days a week
Number of subjects: 32
Study 37782150 — intervention group
Group type: COMPARATOR
Intervention: Control group with IMT at 10% MIP
Number of subjects: 32
Study 37782353 — intervention group
Group type: EXPERIMENTAL
Intervention: AG019 monotherapy (Phase 1b)
Number of subjects: 42
Study 37782353 — intervention group
Group type: EXPERIMENTAL
Intervention: AG019 in combination with teplizumab (Phase 2a)
Number of subjects: 42
Study 37782356 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (UA) levels in early pregnancy
Number of subjects: 873
Study 37782356 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum UA above 240 μmol/l
Number of subjects: 873
Study 37782356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women aged over 35 years and preBMI ≥ 24 kg/m
Number of subjects: 873
Study 37782356 — intervention group
Group type: COMPARATOR
Intervention: Comparison with 78 healthy non-pregnant women
Number of subjects: 873
Study 37782370 — intervention group
Group type: EXPERIMENTAL
Intervention: Global LUS score
Number of subjects: 30
Study 37782370 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-ARDS score
Number of subjects: 30
Study 37782370 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-lateral LUS score
Number of subjects: 30
Study 37782370 — intervention group
Group type: EXPERIMENTAL
Intervention: B-line score
Number of subjects: 30
Study 37782370 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆global LUS score
Number of subjects: 30
Study 37782370 — intervention group
Group type: EXPERIMENTAL
Intervention: ∆anterior-lateral LUS score
Number of subjects: 30
Study 37782421 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced 2D T1-weighted gradient-echo sequences acquired at least 10 min after contrast injection (gadobutrol 0.1 mmol/kg)
Number of subjects: 1
Study 37782421 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced 3D T1-weighted gradient-echo sequences
Number of subjects: 1
Study 37782540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinching Test features
Number of subjects: 67
Study 37782540 — intervention group
Group type: EXPERIMENTAL
Intervention: IMU-based features
Number of subjects: 67